The Moses H. Cone Memorial Hospital
- Type
- Teaching hospital
- Where
- Greensboro, NC
- Medicare CCN
- 340091
- Received
- $1,215,163 in 192 records, 2024 ($82,670 general, $1,132,492 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit: MOSES H CONE MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 56 | $82,670 |
| 2024 | Research payment | 136 | $1,132,492 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 136 | $1,132,492 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 31 | $55,575 |
| Space rental or facility fees (teaching hospital only) | 17 | $16,470 |
| Long term medical supply or device loan | 2 | $6,337 |
| Education | 1 | $2,500 |
| Grant | 1 | $1,000 |
| Debt forgiveness | 3 | $777 |
| Food and Beverage | 1 | $9 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $83,194 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, a | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $11,439 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR, | 2024 |
| 2024-12-31 | Stryker Corporation | $5,026 | Long term medical supply or device loan | In-kind items and services | CORE Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,311 | Long term medical supply or device loan | In-kind items and services | CORE Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $717 | Debt forgiveness | In-kind items and services | 2024 | ||
| 2024-12-17 | Gilead Sciences, Inc. | $2,151 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-12-17 | Gilead Sciences, Inc. | $1,775 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-12-16 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-12-16 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-12-16 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-12-16 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-12-13 | HEARTFLOW, INC. | $3,700 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE) | 2024 |
| 2024-12-12 | Medtronic, Inc. | $32,240 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-12-12 | Edwards Lifesciences Corporation | $30,079 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2024 | |
| 2024-12-12 | Insulet Corporation | $375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-12-10 | Medtronic, Inc. | $26,681 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-12-10 | Gilead Sciences, Inc. | $18,925 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-12-09 | Medtronic, Inc. | $2,400 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-12-06 | Alnylam Pharmaceuticals Inc. | $14,125 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2024 | |
| 2024-12-05 | Insulet Corporation | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-12-05 | Abbott Laboratories | $684 | Research payment | In-kind items and services | FreeStyle Libre 3 Device, DIABETES CARE | Abbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE) | 2024 |
| 2024-12-05 | Abbott Laboratories | $684 | Research payment | In-kind items and services | FreeStyle Libre 3 Device, DIABETES CARE | Abbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE) | 2024 |
| 2024-12-04 | Alnylam Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2024 | |
| 2024-11-27 | Analog Devices Inc. | $32,284 | Research payment | Cash or cash equivalent | Sensinel CPM Wearable Device, CARDIOLOGY | Feasibility and Efficacy Study of the CardioPulmonary Monitoring (CPM) System in Patients with Chronic Heart Failure | 2024 |
| 2024-11-25 | Medtronic, Inc. | $49,750 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-11-21 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-11-21 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-11-19 | Gilead Sciences, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-11-15 | Abbott Laboratories | $684 | Research payment | In-kind items and services | FreeStyle Libre 3 Device, DIABETES CARE | Abbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE) | 2024 |
| 2024-11-14 | Abbott Laboratories | $684 | Research payment | In-kind items and services | FreeStyle Libre 3 Device, DIABETES CARE | Abbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE) | 2024 |
| 2024-11-13 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-11-12 | Edwards Lifesciences Corporation | $28,141 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2024 | |
| 2024-11-06 | Abbott Laboratories | $2,076 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, STRUCTURAL HEART | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2024 |
| 2024-11-04 | HEARTFLOW, INC. | $2,700 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE) | 2024 |
| 2024-10-31 | CVRx, Inc. | $8,980 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-10-31 | CVRx, Inc. | $2,137 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-10-30 | Insulet Corporation | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-30 | Olympus America Inc. | $17 | Debt forgiveness | In-kind items and services | 2024 | ||
| 2024-10-24 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-10-24 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-23 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-10-23 | Surmodics, Inc. | $62 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-10-23 | Surmodics, Inc. | $62 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-10-23 | Surmodics, Inc. | $62 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-10-23 | Surmodics, Inc. | $62 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-10-23 | Surmodics, Inc. | $62 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-10-22 | Gilead Sciences, Inc. | $6,686 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-10-22 | Merck Sharp & Dohme LLC | $600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DIFICID Drug, INFECTIOUS DISEASE | 2024 | |
| 2024-10-16 | Merz Pharmaceuticals, LLC | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Xeomin Biological, Musculoskeletal | 2024 | |
| 2024-10-16 | Insulet Corporation | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-08 | Gilead Sciences, Inc. | $550 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-10-07 | ZOLL Medical Corporation | $400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Defibrillator Device, Resuscitation | 2024 | |
| 2024-10-04 | Siemens Medical Solutions USA, Inc. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | syngo Dynamics Device, SY - Image and Knowledge Management | 2024 | |
| 2024-10-02 | Insulet Corporation | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-30 | HEARTFLOW, INC. | $3,300 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE) | 2024 |
| 2024-09-30 | Medtronic, Inc. | $5 | Research payment | In-kind items and services | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-09-29 | Abbott Laboratories | $1,368 | Research payment | In-kind items and services | FreeStyle Libre 3 Device, DIABETES CARE | Abbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE) | 2024 |
| 2024-09-28 | Abbott Laboratories | $1,368 | Research payment | In-kind items and services | FreeStyle Libre 3 Device, DIABETES CARE | Abbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE) | 2024 |
| 2024-09-26 | Insulet Corporation | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-26 | Siemens Medical Solutions USA, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SOMATOM go.Top Device, CT and RO incl. Computed Tomography and Radiation Oncology | 2024 | |
| 2024-09-26 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-09-25 | Surmodics, Inc. | $3,000 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-09-25 | Surmodics, Inc. | $1,500 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-09-25 | Surmodics, Inc. | $1,000 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-09-25 | Surmodics, Inc. | $1,000 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-09-25 | Surmodics, Inc. | $400 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-09-25 | Surmodics, Inc. | $400 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-09-25 | Surmodics, Inc. | $150 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-09-20 | Insulet Corporation | $2,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-20 | Alnylam Pharmaceuticals Inc. | $1,875 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2024 | |
| 2024-09-20 | Insulet Corporation | $725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-10 | M.A. Med Alliance S.A. | $16,825 | Research payment | Cash or cash equivalent | SELUTION SLR 018 DEB Device, CARDIOVASCULAR | A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Efficacy of the SELUTION SLR 018 Drug | 2024 |
| 2024-09-07 | Ipsen Biopharmaceuticals, Inc | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Onivyde Drug, Oncology | 2024 | |
| 2024-08-30 | HEARTFLOW, INC. | $2,900 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE) | 2024 |
| 2024-08-27 | Gilead Sciences, Inc. | $650 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-08-22 | Siemens Medical Solutions USA, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SOMATOM go.Top Device, CT and RO incl. Computed Tomography and Radiation Oncology | 2024 | |
| 2024-08-21 | Gilead Sciences, Inc. | $5,184 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-08-21 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-19 | Abbott Laboratories | $786 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, STRUCTURAL HEART | AMPLATZER PFO Occluder Post Approval Study | 2024 |
| 2024-08-16 | HEARTFLOW, INC. | $2,600 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE) | 2024 |
| 2024-08-13 | Gilead Sciences, Inc. | $1,350 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-08-09 | Abbott Laboratories | $1,368 | Research payment | In-kind items and services | FreeStyle Libre 3 Device, DIABETES CARE | Abbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE) | 2024 |
| 2024-08-09 | Abbott Laboratories | $684 | Research payment | In-kind items and services | FreeStyle Libre 3 Device, DIABETES CARE | Abbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE) | 2024 |
| 2024-08-09 | Bayer Healthcare Pharmaceuticals Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Nubeqa Drug, Oncology | 2024 | |
| 2024-08-01 | CVRx, Inc. | $12,916 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-08-01 | CVRx, Inc. | $4,862 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-07-31 | Siemens Medical Solutions USA, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SOMATOM go.Top Device, CT and RO incl. Computed Tomography and Radiation Oncology | 2024 | |
| 2024-07-25 | Siemens Medical Solutions USA, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SOMATOM go.Top Device, CT and RO incl. Computed Tomography and Radiation Oncology | 2024 | |
| 2024-07-24 | Tandem Diabetes Care, Inc. | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-07-18 | Siemens Medical Solutions USA, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SOMATOM go.Top Device, CT and RO incl. Computed Tomography and Radiation Oncology | 2024 | |
| 2024-07-17 | CVRx, Inc. | $505 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-07-17 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-07-17 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-07-17 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-07-17 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-07-17 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-07-17 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-07-16 | Gilead Sciences, Inc. | $4,144 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-07-05 | Amgen Inc. | $103,070 | Research payment | In-kind items and services | AAHeart Lpa ChartRev | 2024 | |
| 2024-06-30 | Medtronic, Inc. | $45,480 | Research payment | In-kind items and services | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-06-28 | CSL Behring | $10,276 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-06-26 | Amgen Inc. | $10,845 | Research payment | Cash or cash equivalent | LUMAKRAS Drug, Oncology | P3 3L + Vectibix vs Pi choice CRC CB 300 | 2024 |
| 2024-06-25 | Gilead Sciences, Inc. | $7,699 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-06-25 | Insulet Corporation | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-06-24 | HEARTFLOW, INC. | $4,400 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE) | 2024 |
| 2024-06-18 | Gilead Sciences, Inc. | $1,627 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-06-06 | CVRx, Inc. | $70,758 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-06-06 | Edwards Lifesciences Corporation | $16,079 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2024 | |
| 2024-06-03 | CSL Behring | $90,107 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-06-03 | HEARTFLOW, INC. | $13,000 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE) | 2024 |
| 2024-06-03 | HEARTFLOW, INC. | $7,550 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE) | 2024 |
| 2024-05-28 | Abbott Laboratories | $14 | Research payment | In-kind items and services | FreeStyle Libre 3 Device, DIABETES CARE | Abbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE) | 2024 |
| 2024-05-24 | CSL Behring | $2,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-05-24 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-05-24 | Janssen Pharmaceuticals, Inc | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2024 | |
| 2024-05-24 | CSL Behring | $600 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-05-24 | CSL Behring | $500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-05-23 | Gilead Sciences, Inc. | $100 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-05-21 | Gilead Sciences, Inc. | $4,144 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-05-16 | Insulet Corporation | $18,525 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-05-14 | Gilead Sciences, Inc. | $1,475 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-05-13 | Abbott Laboratories | $234 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, STRUCTURAL HEART | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2024 |
| 2024-05-03 | CVRx, Inc. | $14,949 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-05-03 | CVRx, Inc. | $8,943 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-05-03 | Novartis Pharmaceuticals Corporation | $1,200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MEKINIST Drug, Oncology | 2024 | |
| 2024-04-30 | Merck Sharp & Dohme LLC | $300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DIFICID Drug, INFECTIOUS DISEASE | 2024 | |
| 2024-04-26 | Edwards Lifesciences Corporation | $1,990 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-04-26 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-04-26 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-04-24 | M.A. Med Alliance S.A. | $12,500 | Research payment | Cash or cash equivalent | SELUTION SLR 018 DEB Device, CARDIOVASCULAR | A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Efficacy of the SELUTION SLR 018 Drug | 2024 |
| 2024-04-22 | Edwards Lifesciences Corporation | $995 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SAPIEN 3 Ultra RESILIA Device, Transcatheter Heart Valves | 2024 | |
| 2024-04-22 | ConvaTec Inc. | $400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ESTEEM+ Device, OSTOMY CARE | 2024 | |
| 2024-04-22 | Abbott Laboratories | $14 | Research payment | In-kind items and services | FreeStyle Libre 3 Device, DIABETES CARE | Abbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE) | 2024 |
| 2024-04-20 | Amgen Inc. | $85,386 | Research payment | Cash or cash equivalent | OCEANa-Outcomes P3 CV | 2024 | |
| 2024-04-20 | Amgen Inc. | $4,500 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | 20170625_VESALIUS - CV | 2024 |
| 2024-04-19 | E.R. Squibb & Sons, L.L.C. | $1,200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-04-19 | ARRAY BIOPHARMA INC | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-04-19 | Merck Sharp & Dohme LLC | $650 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VERQUVO Drug, CARDIOVASCULAR | 2024 | |
| 2024-04-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $995 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-04-17 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-16 | Gilead Sciences, Inc. | $4,668 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-04-16 | Gilead Sciences, Inc. | $600 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-04-11 | Alnylam Pharmaceuticals Inc. | $995 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2024 | |
| 2024-04-02 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-03-31 | Medtronic, Inc. | $6,501 | Research payment | In-kind items and services | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-03-29 | Olympus America Inc. | $43 | Debt forgiveness | In-kind items and services | 2024 | ||
| 2024-03-28 | AstraZeneca Pharmaceuticals LP | $995 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-03-27 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-03-25 | Amgen Inc. | $8,153 | Research payment | In-kind items and services | Repatha Biological, Cardiology | 20170625_VESALIUS - CV | 2024 |
| 2024-03-25 | CMS Imaging, Inc. | $9 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-03-22 | CSL Behring | $10,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-22 | Insulet Corporation | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-03-22 | CSL Behring | $2,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-22 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-22 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-22 | CSL Behring | $900 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-22 | CSL Behring | $350 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-21 | Insulet Corporation | $4,775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-03-20 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-03-19 | Gilead Sciences, Inc. | $1,556 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-03-18 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-03-18 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-03-18 | Medtronic, Inc. | $450 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2024 |
| 2024-02-27 | Gilead Sciences, Inc. | $100 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-02-22 | Gilead Sciences, Inc. | $5,184 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-02-19 | Abbott Laboratories | $2,801 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, STRUCTURAL HEART | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2024 |
| 2024-02-16 | AstraZeneca Pharmaceuticals LP | $1,700 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab | 2024 |
| 2024-02-16 | Surmodics, Inc. | $62 | Research payment | Cash or cash equivalent | SurVeil Drug-Coated Balloon Device, Drug Coated Balloon | Safety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND) | 2024 |
| 2024-02-15 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | Medtronic, Inc. | $375 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2024 |
| 2024-02-15 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-12 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, STRUCTURAL HEART | OSB Lead-AMPLATZERPFOOccluder New EnrollmentPAS | 2024 |
| 2024-02-01 | Gilead Sciences, Inc. | $700 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-01-31 | Amgen Inc. | $40,426 | Research payment | In-kind items and services | Repatha Biological, Cardiology | ACS-REAL Pragmatic study EVOLVE MI | 2024 |
| 2024-01-31 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-01-25 | Novo Nordisk Inc | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-01-24 | CVRx, Inc. | $12,249 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-01-24 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,000 | Grant | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2024 | |
| 2024-01-23 | iRhythm Technologies, Inc. | $2,500 | Education | Cash or cash equivalent | ZIO XT Patch Device, Cardiology/Vascular Diseases | 2024 | |
| 2024-01-22 | Medtronic, Inc. | $525 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2024 |
| 2024-01-18 | CVRx, Inc. | $9,925 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-01-18 | Gilead Sciences, Inc. | $4,144 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-01-17 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-01-10 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-01-08 | Amgen Inc. | $20,544 | Research payment | In-kind items and services | OCEANa-Outcomes P3 CV | 2024 | |
| 2024-01-04 | Boehringer Ingelheim International GmbH | $3,360 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin for prevention of HHF and death after an AMI | 2024 |
| 2024-01-02 | Medtronic, Inc. | $12,812 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-01-02 | Gilead Sciences, Inc. | $2,100 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-01-01 | Caption Health, Inc. | $14,419 | Research payment | Cash or cash equivalent | Device, Lung Guidance | Lung Guidance | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Greensboro, NC, county Guilford County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Greensboro, NC | County Guilford County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 301,198 | 547,940 | 10,730,404 |
| Population, 2020 census P1 | 299,035 | 541,299 | 10,439,388 |
| Median age B01002 | 34.3 | 37.5 | 39.1 |
| Under 18 B01001 | 21.7% | 22.0% | 21.8% |
| 65 and over B01001 | 14.4% | 15.9% | 17.2% |
| Households B11001 | 123,984 | 219,718 | 4,282,345 |
| Foreign born B05002 | 12.7% | 11.8% | 9.1% |
| Median household income B19013 | $61,515 | $68,642 | $72,388 |
| Median family income B19113 | $80,585 | $88,156 | $90,290 |
| Per capita income B19301 | $37,531 | $39,376 | $41,385 |
| Poverty rate B17001 | 17.0% | 14.6% | 13.0% |
| Unemployment rate B23025 | 5.1% | 4.6% | 4.7% |
| Civilian labor force B23025 | 158,568 | 282,362 | 5,336,863 |
| Mean commute (minutes) B08013 | 21.7 | 22.0 | 25.1 |
| Bachelor's degree or higher B15003 | 41.0% | 39.0% | 35.7% |
| Housing units B25001 | 135,665 | 238,032 | 4,895,668 |
| Owner-occupied B25003 | 50.5% | 59.9% | 66.6% |
| Renters B25003 | 49.5% | 40.1% | 33.4% |
| Median home value B25077 | $244,800 | $259,900 | $288,900 |
| Median gross rent B25064 | $1,172 | $1,163 | $1,228 |
| White, not Hispanic B03002 | 38.1% | 46.0% | 60.0% |
| Black B03002 | 41.0% | 33.5% | 20.0% |
| Hispanic or Latino B03002 | 10.5% | 10.1% | 11.3% |
| Asian B03002 | 5.2% | 5.4% | 3.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greensboro, NC.
Comments